Bear ... well played by RVX indeed!

Quick internet search showed 2019 SGLT2 sales:

Jardiance:  $944.2m

Farxiga:  $1.54b

An extra 10 years of patent life potentially protecting those revenues, when combined with apabetalone?

Plus whatever incremental clinical/competitive market "growth" value for the partnering SGLT2 in combination with apabetalone, that may be brought to light (and "proven") in BoM2?

There are numerous parts and ways to look at the value proposition for RVX, for negotiating. Just the patent extension could be worth $5-10b for a partnering BP with an SGLT2 ... of course there could be other strategies, or follow up drugs in the pipeline, or patent extensions in the works by those companies as well.

Even just a solid BoM2 could be VERY profitable for a lot of folks all around the table.

Hmmmmm ......